KILITCH

Kilitch Drugs(I) Share Price

 

 

Start SIP in KILITCH

Start SIP

Performance

  • Low
  • ₹321
  • High
  • ₹340
  • 52 Week Low
  • ₹294
  • 52 Week High
  • ₹500
  • Open Price₹340
  • Previous Close₹337
  • Volume20,429

Investment Returns

  • Over 1 Month -14.8%
  • Over 3 Month -12.58%
  • Over 6 Month -25.58%
  • Over 1 Year -1.95%

Smart Investing Starts Here Start SIP with Kilitch Drugs(I) for Steady Growth!

Invest Now

Kilitch Drugs(I) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 20.5
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 565
  • P/B Ratio
  • Average True Range
  • 13.64
  • EPS
  • 15.77
  • Dividend Yield
  • 0
  • MACD Signal
  • -6.69
  • RSI
  • 27.65
  • MFI
  • 19.47

Kilitch Drugs(I) Financials

Kilitch Drugs(I) Technicals

EMA & SMA

Current Price
₹323.35
-13.25 (-3.94%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹350.66
  • 50 Day
  • ₹362.23
  • 100 Day
  • ₹372.35
  • 200 Day
  • ₹372.11

Resistance and Support

328.07 Pivot Speed
  • R3 353.53
  • R2 346.62
  • R1 334.98
  • S1 316.43
  • S2 309.52
  • S3 297.88

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Kilitch Drugs India has an operating revenue of Rs. 209.46 Cr. on a trailing 12-month basis. An annual revenue growth of 32% is outstanding, Pre-tax margin of 17% is great, ROE of 13% is good. The company has a reasonable debt to equity of 14%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 32% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 88 which is a GOOD score indicating consistency in earnings, a RS Rating of 55 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Kilitch Drugs(I) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-13 Quarterly Results
2025-07-02 Others Inter-alia, to consider 1. Fund Raising by way of issue of equity shares of face value of 10/-each through Rights Issue. 2. Deployment of the proceeds of the Right Issue. 3. Other business matters. issue of equity shares of Rs. 10/- in the ratio of 2:23 @ premium of Rs. 347/-.
2025-05-19 Audited Results
2025-02-11 Quarterly Results

Kilitch Drugs(I) F&O

Kilitch Drugs(I) Shareholding Pattern

63.77%
0%
0%
0%
0%
30.22%
6.01%

About Kilitch Drugs(I)

  • NSE Symbol
  • KILITCH
  • BSE Symbol
  • 524500
  • Managing Director
  • Mr. Mukund P Mehta
  • ISIN
  • INE729D01010

Similar Stocks to Kilitch Drugs(I)

Kilitch Drugs(I) FAQs

Kilitch Drugs(I) share price is ₹323 As on 09 December, 2025 | 01:14

The Market Cap of Kilitch Drugs(I) is ₹565.2 Cr As on 09 December, 2025 | 01:14

The P/E ratio of Kilitch Drugs(I) is 20.5 As on 09 December, 2025 | 01:14

The PB ratio of Kilitch Drugs(I) is 2.2 As on 09 December, 2025 | 01:14

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23